<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75615">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01991444</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1149-9951</org_study_id>
    <secondary_id>DRKS00005436</secondary_id>
    <nct_id>NCT01991444</nct_id>
  </id_info>
  <brief_title>CGA-TAVI Registry to Evaluate the Predictive Value of a CGA in Predicting TAVI Outcomes</brief_title>
  <acronym>CGA-TAVI</acronym>
  <official_title>Registry Study to Evaluate the Predictive Value of a Comprehensive Geriatric Assessment With Regard to the Outcome of a Transcatheter Aortic Valve Implantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Registry study to evaluate the predictive value of a comprehensive geriatric assessment with
      regard to the outcome of a transcatheter aortic valve Implantation.

      It will be evaluated which parts of the comprehensive geriatric assessment (CGA) are best
      suited to predict the therapeutic success of a heart valve Implantation in elderly ( &gt; 80
      years) Patient. Possible participants are all Patient of 80 years or above for whom the
      implantation of a Edwards Sapien XT aortic valve is planned
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transcatheter Aortic Valve Implantation Registry with Comprehensive Geriatric Assessment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Comprehensive geriatric assessment</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Demonstrate CGA changes within 3 months after TAVI
The CGA is an array of several different assessments with regard to frailty, comorbidities, administrative data (Silver code), Quality of life etc. Every Patient will undergo a CGA at baseline and 3 months after TAVI. Data will be analyzed to determine changes in CGA results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>predictive Value of CGA Tavi</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Establish predictive value of CGA (MPI, SPPB, SilverCode) in TAVI patients for all-cause hospitalization, TAVI related hospitalization, nursing home admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score development</measure>
    <time_frame>after 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Development of a comprehensive score for the assessment of TAVI patient prognosis (identifying variables from the MPI, SPPB and SilverCode that account for 80% of the predictive power of the complete set)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>TAVI patients of &gt; 79 years</arm_group_label>
    <description>All patients undergoing transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve in participating sites.
Routine data about the intervention (transcatheter valve Implantation) will be collected. In addition, data describing the geriatric status of the patient, including a patient questionnaire evaluating his/her Quality of life will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TAVI</intervention_name>
    <description>no Intervention planned, Observation only</description>
    <arm_group_label>TAVI patients of &gt; 79 years</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients undergoing transcatheter valve implantation with commercially available
        Edwards SAPIEN XT Transcatheter Heart Valve in participating sites.

        Routine data about the invervention (transcatheter valve Implantation) will be collected.
        In addition, data describing the geriatric status of the patient, including a patient
        questionnaire evaluating his/her Quality of life will be collected.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled TAVI using Edwards SAPIEN XT Transcatheter Heart Valve

          -  Compliance with the indications of the instructions for use

          -  Age of at least 80 years

          -  Written informed consent

        Exclusion Criteria:

          -  Presence of contraindications as to the Instructions for Use

          -  No possibility for a follow-up
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Ungar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geriatric Cardiology and Medicine - U. of  Florence</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Bramlage, MD</last_name>
    <phone>+494471850</phone>
    <phone_ext>3339</phone_ext>
    <email>peter.bramlage@ippmed.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerstin Plate</last_name>
    <phone>+494471850</phone>
    <phone_ext>3331</phone_ext>
    <email>kerstin.plate@ippmed.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nikos Werner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza Istituto Ospedaliero</name>
      <address>
        <city>Brescia</city>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renzo Rozzini, MD</last_name>
      <email>rozzini-renzo@poliambulanza.it</email>
    </contact>
    <investigator>
      <last_name>Renzo Rozzini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea Ungar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>November 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
